Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 3768

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Dr Zahi Mitri talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from a trial looking at olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.

He explains that olaparib is approved for treatment for patients with BRCA germline breast cancer and the goal of this study is to see if this combination works for patients outside of that group.

Dr Mitri explains that the study is ongoing and hopes that results will start coming in at the end of the year.

This programme has been supported by an unrestricted educational grant from Pfizer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation